Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation
Clinical Pharmacokinetics · 2024
DOI: 10.1007/s40262-024-01392-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Kimitaka Suetsugu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Antiviral Agents, Quinazolines, Acetates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 129 Literaturangaben. Gefördert von: Kaken Pharmaceutical.
Abstract (Originalsprache)
Letermovir is a newly developed antiviral agent used for the prophylaxis of human cytomegalovirus infections in patients undergoing allogeneic hematopoietic cell transplantation. This novel anti-cytomegalovirus drug, used for the prophylaxis of cytomegalovirus reactivation until approximately 200 days after transplantation, effectively reduces the risk of clinically significant cytomegalovirus infection. No human counterpart exists for the terminase complex; letermovir is virus specific and lacks some toxicities previously observed with other anti-cytomegalovirus drugs, such as cytopenia and nephrotoxicity. The absolute bioavailability of letermovir in healthy individuals is estimated to be 94% based on a population-pharmacokinetic analysis. In contrast, oral administration of letermovir to patients undergoing hematopoietic cell transplantation results in lower exposure than that in healthy individuals. Renal or hepatic impairment does not influence the intrinsic clearance of letermovir. Co-administration of letermovir may alter the plasma concentrations of other drugs, including itself, as it acts as a substrate and inhibitor/inducer of several drug-metabolizing enzymes and transporters. In particular, attention should be paid to the drug-drug interactions between letermovir and calcineurin inhibitors or azole antifungal agents, which are commonly used in patients undergoing hematopoietic cell transplantation. This article reviews and summarizes the clinical pharmacokinetics and pharmacodynamics of letermovir, focusing on patients undergoing hematopoietic cell transplantation, healthy individuals, and specific patient subsets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
- Department of Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
- Department of Pharmacy, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. ieiri@phar.kyushu-u.ac.jp.
- Department of Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. ieiri@phar.kyushu-u.ac.jp.
Förderung
- Kaken Pharmaceutical
Zitieren
APA
Suetsugu, K., Shigematsu, T., Nakamura, T., Hirota, T., & Ieiri, I. (2024). Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01392-1
Vancouver
Suetsugu K, Shigematsu T, Nakamura T, Hirota T, Ieiri I. Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01392-1
BibTeX
@article{Suetsugu2024,
author = {Suetsugu, Kimitaka and Shigematsu, Tomohiro and Nakamura, Takahiro and Hirota, Takeshi and Ieiri, Ichiro},
title = {Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation},
journal = {Clinical Pharmacokinetics},
year = {2024},
doi = {10.1007/s40262-024-01392-1}
}
EUVIMED